Almirall, S.A./€ALM

05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX

About Almirall, S.A.

Almirall, S.A. is a pharmaceutical company headquartered in Barcelona, Spain. It specializes in the development and commercialization of proprietary medicines, with a focus on dermatology and other specialist-driven therapeutic areas. Almirall's notable products target conditions such as psoriasis, atopic dermatitis, and actinic keratosis. Founded in 1943, the company has expanded its geographical footprint across Europe and North America through strategic acquisitions and partnerships. Almirall emphasizes research and development, maintaining a pipeline of innovative treatments aimed at unmet medical needs. Its strategic positioning is reinforced by collaborations with healthcare professionals and institutions to enhance patient care.

Ticker

€ALM

Primary listing

BME

Industry

Pharmaceuticals
Headquarters

Employees

2,026

ISIN

ES0157097017

Almirall, S.A. Metrics

BasicAdvanced
€2.3B
93.03
€0.11
0.30
€0.15
1.40%

Bulls say / Bears say

Almirall's stock has surged over 30% since January 2025, increasing its market capitalization by €642 million to €2.645 billion, reflecting strong investor confidence. (cincodias.elpais.com)
The company reported a 15% increase in total sales in Q1 2025, reaching €284 million, with a 35% rise in EBITDA to €70.9 million, indicating robust financial health. (cincodias.elpais.com)
Almirall's strategic licensing agreement with Novo Nordisk for the monoclonal antibody NN-8828 positions it to develop treatments for inflammatory and dermatological diseases, potentially expanding its product portfolio. (marketscreener.com)
Despite revenue growth, Almirall's net income for Q1 2025 was €24.35 million, resulting in a high P/E ratio of 98.20, which may indicate overvaluation. (stockanalysis.com)
The company's net profit margin in Q1 2025 was 1.14%, suggesting that increased revenues are not translating into proportional profitability. (google.com)
Almirall's stock price has experienced volatility, with a 52-week range between €8.03 and €11.30, which may concern risk-averse investors. (stockanalysis.com)
Data summarised monthly by Lightyear AI. Last updated on 27 Jun 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €ALM

Sign up or log in to buy
Capital at risk
Extended hours trading

Upcoming events

No upcoming events
FAQs